

## Velcade® (bortezomib) (Intravenous/Subcutaneous)

Document Number: IC-0137

Last Review Date: 12/04/2018

Date of Origin: 11/28/2011

Dates Reviewed: 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018

### I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- Velcade 3.5 mg powder for injection: 4 vials per 21 day supply

#### B. Max Units (per dose and over time) [Medical Benefit]:

- 140 billable units every 21 days

### III. Initial Approval Criteria

Coverage is provided in the following conditions:

- Patient aged 18 years or older; **AND**

#### Multiple myeloma †

- Used as primary therapy for active (symptomatic) disease or for relapse after 6 months following primary induction therapy; **OR**
- Used as maintenance therapy as a single agent; **OR**
- Used as therapy for relapse or progressive disease

#### Mantle cell lymphoma †

- Used as initial therapy in transplant ineligible patients as a component of VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone); **OR**
- Used as second-line therapy for extended response to prior chemoimmunotherapy as a single agent or in combination with rituximab

### **Systemic Light Chain Amyloidosis †**

- Patient is newly diagnosed; **AND**
  - Used in combination with cyclophosphamide and dexamethasone; **OR**
  - Used as a single agent; **OR**
  - Used in combination with dexamethasone with or without melphalan; **OR**
- Patient has relapsed or refractory disease§; **AND**
  - Used as a single agent; **OR**
  - Used in combination with dexamethasone with or without melphalan

*§Consider repeating initial therapy if relapse-free for several years*

### **Waldenström's macroglobulinemia/Lymphoplasmacytic Lymphoma †**

- Used in combination with dexamethasone and rituximab; **OR**
- Used as a single agent or in combination with rituximab; **OR**
- Used in combination with dexamethasone; **OR**

### **Multicentric Castleman's Disease †**

- Must be used as subsequent therapy; **AND**
- Patient has progressed following treatment for relapsed/refractory or progressive disease; **AND**
- Used as a single agent or in combination with rituximab

### **Primary cutaneous CD30+ T-Cell Lymphoproliferative Disorders †**

- Used as single agent for relapsed or refractory disease; **AND**
  - Patient has primary cutaneous anaplastic large cell lymphoma (pcALCL) with multifocal lesions; **OR**
  - Patient has cutaneous ALCL with regional nodes (excludes systemic ALCL)

### **Adult T-Cell Leukemia/Lymphoma †**

- Must be used as a single agent for non-responders to first-line therapy for acute disease or lymphoma; **AND**
  - Used second-line if intent is to proceed to high-dose therapy with allogeneic stem cell rescue (HDT/ASCR); **OR**
  - Subsequent therapy after HDT/ASCR

† FDA Approved Indication(s); ‡ Compendia recommended indication(s)

## **IV. Renewal Criteria**

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the criteria identified in section III; **AND**
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Example of unacceptable toxicity include: peripheral neuropathy, hypotension, cardiac toxicity, pulmonary toxicity, posterior reversible encephalopathy syndrome, gastrointestinal toxicity, thrombocytopenia, neutropenia, tumor lysis syndrome, hepatic toxicity, etc.

## V. Dosage/Administration

Indication	Dose
Multiple myeloma - previously untreated	1.3 mg/m <sup>2</sup> IV/SC in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles. In cycles 1-4, Velcade is given twice weekly (days 1, 4, 8, 11, 22, 25, 29, and 32). In cycles 5-9, Velcade is given once weekly (days 1, 8, 22, and 29).
Mantle Cell Lymphoma – previously untreated	1.3 mg/m <sup>2</sup> IV/SC in combination with rituximab, cyclophosphamide, doxorubicin, and oral prednisone for six 3-week cycles. Velcade is given twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period on Days 12-21. For patients with a response first documented at cycle 6, two additional cycles are recommended.
Multiple myeloma & Mantle Cell Lymphoma- relapsed	1.3 mg/m <sup>2</sup> IV/SC twice weekly x 4 doses (days 1, 4, 8, and 11) followed by a 10-day rest period (days 12-21). <ul style="list-style-type: none"> <li>• For extended therapy of more than 8 cycles, bortezomib may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest period (days 23 to 35)</li> </ul>
Waldenström’s macroglobulinemia	<ul style="list-style-type: none"> <li>• 1.3 mg/m<sup>2</sup> IV/SC twice weekly for 2 weeks (days 1, 4, 8, and 11) in a 21 day cycle</li> <li>• In combination with rituximab alone: 1.6mg/m<sup>2</sup> days 1, 8, and 15 of a 28 day cycle</li> </ul>
All Other Indications	1.3 mg/m <sup>2</sup> IV/SC twice weekly (days 1, 4, 8, and 11) for 2 weeks of a 21 day cycle

## VI. Billing Code/Availability Information

### Jcode:

- J9041– Injection, bortezomib (velcade), 0.1 mg; 1 billable unit = 0.1 mg

### NDC(s):

- Velcade 3.5 mg single-use vial powder for injection: 63020-0049-xx

## VII. References

1. Velcade [package insert]. Cambridge, MA; Millennium Pharmaceuticals, Inc; June 2017. Accessed November 2018.

2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Bortezomib. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed November 2018.
3. Boccadoro M, Bringhen S, Gaidano G, et al, “Bortezomib, Melphalan, Prednisone, and Thalidomide (VMPT) Followed by Maintenance With Bortezomib and Thalidomide (VT) for Initial Treatment of Elderly Multiple Myeloma Patients,” *J Clin Oncol*, 2010, 28(7s):8013 [abstract 8013 from 2010 ASCO Annual Meeting].
4. Palumbo A, Bringhen S, Rossi D, et al, “Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance With Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients,” *Blood*, 2009, 114(22):128 [abstract 128 from ASH 2009 Annual Meeting].
5. Ghobrial IM, Hong F, Padmanabhan S, et al, “Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia,” *J Clin Oncol*, 2010, 28(8):1422-8.
6. First Coast Service Options, Inc. Local Coverage Determination (LCD): Bortezomib (Velcade®) (L33273) Centers for Medicare & Medicare Services, Inc. Updated on 2/2/2018 with effective date 2/8/2018. Accessed November 2018.
7. National Government Services, Inc. Local Coverage Article for Bortezomib – Related to LCD L33394 (A52371). Centers for Medicare & Medicaid Services, Inc. Updated on 4/6/2018 with effective date of 4/15/2018. Accessed November 2018.
8. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) T-Cell Lymphomas. Version 5.2018. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed November 2018.
9. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Systemic Light Chain Amyloidosis. Version 1.2019. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed November 2018.
10. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 2.2019. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER

NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed November 2018.

11. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) B-Cell Lymphomas. Version 5.2018. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed November 2018.
12. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Multiple Myeloma. Version 1.2019. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed November 2018.
13. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-4297.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C83.00	Small cell B-cell lymphoma, unspecified site
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face and neck
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
C83.03	small cell B-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell B-cell lymphoma, spleen
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
C83.10	Mantle cell lymphoma, unspecified site
C83.11	Mantle cell lymphoma, lymph nodes of head, face and neck
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb

### VELCADE® (bortezomib) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2018, Magellan Rx Management

ICD-10	ICD-10 Description
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes
C83.17	Mantle cell lymphoma, spleen
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites
C83.19	Mantle cell lymphoma, extranodal and solid organ sites
C86.6	Primary cutaneous CD30-positive T-cell proliferations
C88.0	Waldenstrom macroglobulinemia
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma, in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.11	Plasma cell leukemia in remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.21	Extramedullary plasmacytoma in remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.31	Solitary plasmacytoma in remission
C90.32	Solitary plasmacytoma in relapse
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse
D36.0	Benign neoplasm of lymph nodes
D47.Z2	Castleman disease
E85.81	Light chain (AL) amyloidosis
E85.89	Other amyloidosis
E85.9	Amyloidosis, unspecified
R59.0	Localized enlarged lymph nodes
R59.1	Generalized enlarged lymph nodes
R59.9	Enlarged lymph nodes, unspecified
Z85.72	Personal history of non-Hodgkin lymphomas
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

**Dual coding requirements:**

- Codes Z85.72 & Z85.79 are secondary codes and must be billed in conjunction with a primary code

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

<b>Jurisdiction(s):</b> N	<b>NCD/LCD Document (s):</b> L33273
<a href="https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=L33273&amp;bc=gAAAAAAAAAAAAAA==">https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=L33273&amp;bc=gAAAAAAAAAAAAAA==</a>	
<b>Jurisdiction(s):</b> 6, K	<b>NCD/LCD Document (s):</b> A52371
<a href="https://www.cms.gov/medicare-coverage-database/search/article-date-search.aspx?DocID=A52371&amp;bc=gAAAAAAAAAAAAAA==">https://www.cms.gov/medicare-coverage-database/search/article-date-search.aspx?DocID=A52371&amp;bc=gAAAAAAAAAAAAAA==</a>	

### Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC